Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.

Artemiadis, A K; Nikolaou, G; Kolokythopoulos, D; Tegos, N; Terentiou, A; Triantafyllou, N; Papanastasiou, I

Artemiadis, A K; Nikolaou, G; Kolokythopoulos, D; Tegos, N; Terentiou, A; Triantafyllou, N; Papanastasiou, I.

Afiliação

Artemiadis AK; 1st Department of Neurology, Aeginition Hospital, School of Medicine, Kapodistrian University of Athens, Athens, Greece kmwartem@yahoo.com.
Nikolaou G; Department of Neurology, NIMTS Hospital, Athens, Greece.
Kolokythopoulos D; Department of Hematology, NIMTS Hospital, Athens, Greece.
Tegos N; Hellenic Centre for Diseases Control and Prevention, Ministry of Health, Athens, Greece.
Terentiou A; Department of Neurology, NIMTS Hospital, Athens, Greece.
Triantafyllou N; 1st Department of Neurology, Aeginition Hospital, School of Medicine, Kapodistrian University of Athens, Athens, Greece.
Papanastasiou I; Department of Neurology, NIMTS Hospital, Athens, Greece.

Mult Scler ; 21(6): 795-6, 2015 May.

Article em En | MEDLINE | ID: mdl-25432949

Assuntos

Cloridrato de Fingolimode/efeitos adversos; Imunossupressores/efeitos adversos; Leishmaniose Visceral/diagnóstico; Esclerose Múltipla/tratamento farmacológico; Adulto; Feminino; Humanos; Leishmaniose Visceral/imunologia

Palavras-chave

Visceral; fingolimod; infection; leishmaniasis; multiple sclerosis; side-effect

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cloridrato de Fingolimode / Imunossupressores / Leishmaniose Visceral / Esclerose Múltipla Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google